Labcorp Holdings Inc. (LH) Stock Price: $266.16+0.89 (+0.34%)
At close: Jun 12, 2026, 4:00 PM ET
The closing share price for Labcorp Holdings Inc. (LH) stock was $266.16 for Friday, June 12, 2026, up 0.34% on the day.
Longer view (total return, dividends reinvested): past 12 months +2.8% · 3-year avg +12.7%/yr · 5-year avg +4.8%/yr
LH Price Chart
LH Key Metrics
See All MetricsLH Earnings Preview
Next Earnings Date
Jul 23, 2026
39 days away
EPS Estimate
4.79
Revenue Est.
$3.71B
Last Quarter Results
EPS
$4.25
vs Estimate
$4.12
Revenue
$3.54B
vs Estimate
$3.51B
LH Analyst Ratings
Consensus Rating
Based on 17 analysts
Average Price Target
$310.12
+16.5% upside
Low
$270.00
Current
$266.16
High
$340.00
LH Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $4.51 | $4.53 | $4.55 | 3 |
| Q2 2027 | $5.16 | $5.18 | $5.20 | 5 |
| Q3 2027 | $4.94 | $4.96 | $4.98 | 3 |
| Q4 2027 | $4.74 | $4.76 | $4.78 | 6 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $18.62 | $19.49 | $20.00 | 12 |
| FY 2028 | $19.05 | $21.18 | $23.98 | 8 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $3.69B | $3.70B | $3.71B | 3 |
| Q2 2027 | $3.86B | $3.87B | $3.89B | 2 |
| Q3 2027 | $3.89B | $3.90B | $3.92B | 2 |
| Q4 2027 | $3.85B | $3.86B | $3.88B | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $15.18B | $15.41B | $15.67B | 14 |
| FY 2028 | $16.12B | $16.13B | $16.14B | 12 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
Related Stocks
HealthcareLH Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LH | $21.83B | $266.16 | +0.34% | +2.80% | +4.75% | +9.60% | — |
| 2MTD | $22.86B | $1131.49 | -0.86% | -4.78% | -3.11% | +11.59% | vs LH |
| 3BNTX | $22.90B | $90.54 | +1.12% | -13.71% | -17.39% | N/A | vs LH |
| 4UTHR | $23.17B | $545.96 | +0.10% | +90.89% | +24.96% | +17.22% | vs LH |
| 5WAT | $23.17B | $355.53 | -1.17% | +1.71% | +1.10% | +9.92% | vs LH |
| 6MRNA | $19.80B | $49.91 | +0.54% | +82.56% | -25.58% | N/A | vs LH |
LH Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter